Corrects paragraph 3 in May 28 story to say "eye drop", not "liquid medication"
May 28 (Reuters) - Eye-care drugmaker Alcon ALCC.S said on Wednesday that the U.S. Food and Drug Administration has approved its treatment for dry eye disease (DED).
Spun off from Novartis NOVN.S in 2019, Alcon is betting on new product launches to accelerate sales growth in the second half of 2025 and beyond.
The approval was based on late-stage studies in which the eye drop, Tryptyr, demonstrated natural tear production as early as day one.
The company said Tryptyr stimulates corneal sensory nerves to quickly increase natural tear production.
DED is a condition in which the eyes either do not produce enough tears or produce poor-quality tears, leading to discomfort and potentially affecting vision.
The company said about 38 million individuals in the United States suffer from DED, yet fewer than 10% of diagnosed patients are being treated with a prescription product.
Alcon, which produces contact lenses, dry eye drops, gels and other related products, expects to launch Tryptyr in the United States during the third quarter of 2025, with plans to introduce the treatment in other markets later.
Other FDA-approved treatments for DED include Alcon's Eysuvis and Bausch + Lomb's BLCO.TO Xiidra.
Last month, however, the FDA declined to approve Aldeyra Therapeutics' ALDX.O treatment for DED.
(Reporting by Puyaan Singh in Bengaluru; Editing by Mohammed Safi Shamsi)
((Puyaan.Singh@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。